(UroToday.com) The 2024 ESMO annual meeting included a session on urothelial carcinoma, featuring a presentation by Dr. Alexandra Drakaki, discussing ctDNA clearance with neoadjuvant durvalumab + ...

This study, presented at SNMMI 2025, aimed to further evaluate the safety profile and determine the optimal therapeutic dose of 177 Lu-P17-088, while also exploring its preliminary efficacy in the ...

SNMMI annual meeting featured a prostate cancer session and a presentation by Dr. Sabina Dizdarevic discussing sequencing and combining beta and alpha targeted radionuclide treatments in the ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Huipan Liu ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Gary Ulaner ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL between May 30 and June 3 was host to the Poster Session: Genitourinary Cancer - Kidney and ...

(UroToday.com) The 2025 ASCO annual meeting featured a urothelial carcinoma oral abstract session and a presentation by Dr. Jeannie Hoffman-Censits discussing an interim analysis from the JAVELIN ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and dosimetry session and a presentation by Dr. Loic Djaileb discussing clinical protocols to monitor efficacy of 177 Lu-PSMA ...

Pre-therapeutic PSMA PET/CT information can be used to predict 177 Lu-PSMA-617 therapy response patterns and outcomes, with various quantitative and visual methods proposed. This study, presented at ...

(UroToday.com) The 2025 SNMMI annual meeting featured a prostate cancer and molecular imaging session and a presentation by Dr. Jiarou Wang discussing the first human study of 68 Ga-P17-079 in ...

SNMMI annual meeting featured a radiotheranostics session and a presentation by Dr. Xuejen Wen discussing the development of PSMA targeting radioligand 161 Tb-LNC1011 for prostate cancer theranostics.

Dr. Kevin Leung presented an artificial intelligence-based risk score for the prognostic evaluation of prostate cancer patients using PSMA PET/CT imaging. Dr. Leung argued that improved survival ...